JPMorgan Maintains Overweight Rating on Cigna (CI) Following Express Scripts Update

Group 1 - The Cigna Group is recognized as one of the 13 Most Undervalued Dividend Stocks to Buy according to Wall Street Analysts [1] - JPMorgan has maintained an Overweight rating on Cigna following an update regarding its Evernorth unit and a new model for Express Scripts starting in 2027 [2][3] - The new model for Express Scripts eliminates rebates and introduces a point-of-sale approach, allowing customers to pay a net price at the time of dispensing [3][4] Group 2 - The analyst believes the change addresses several regulatory proposals and should "de-risk" Express Scripts' commercial operations [4] - Cigna's shift to a de-linked and rebate-free default offering is seen as a viable approach for the broader business [4] - Cigna has increased its dividend for five consecutive years, with a current dividend yield of 2.02% as of October 29 [4]